B

BiohacksAI

Evidence-Based Biohacking

Patent Pending

MAP4K2

MOLECULAR TARGET

mitogen-activated protein kinase kinase kinase kinase 2

UniProt: Q12851NCBI Gene: 587122 compounds

MAP4K2 (mitogen-activated protein kinase kinase kinase kinase 2) is targeted by 22 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).

Compounds Targeting MAP4K2

Ranked by bioassay confidence score (PubChem active assay count × evidence quality).

#CompoundConfidenceActive Assays
1Carvedilol1.393
2amn0821.102
3Aripiprazole1.102
4Astemizole Antihistamine drug now withdrawn from1.102
5Crizotinib1.102
6Fluspirilene1.102
7Duloxetine Hydrochloride0.691
8Melatonin0.691
9alsterpaullone0.691
10Axitinib0.691
11Bumetanide0.691
12Cinnarizine0.691
13Doxazosin0.691
14Harmaline0.691
15Imatinib Mesylate0.691
16Metergoline0.691
17Oleanolic Acid0.691
18Perphenazine0.691
19sp6001250.691
20Thioridazine0.691
21Tinidazole0.691
22triflupromazine hydrochloride0.691

About MAP4K2 as a Drug Target

MAP4K2 (mitogen-activated protein kinase kinase kinase kinase 2) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 22 compounds with documented MAP4K2 interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.

MAP4K2 inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.